Prostate-specific antigen (PSA) screening has led to a remarkable increase in prostate cancer cases undergoing operative therapy. Over half of patients with locally advanced cancer (^pT3) develop rising PSA levels (biochemical failure) within 10 years. It is very difficult to predict which patients will progress rapidly to advanced disease following biochemical failure (BF). Therefore, a more useful prognostic factor is needed to suggest the most appropriate therapies for each patient. To determine chromosomal aberrations, we examined 30 patients with stage pT2 or pT3 primary prostate adenocarcinomas and no metastases (pN0M0) by comparative genomic hybridization (CGH). Laser capture microdissection (LCM) was used to gather cancer cells from frozen prostate specimens. Common chromosomal alterations included losses on 2q23-24, 4q26-28, 6q14-22, 8p12-22 and 13q21-31, as well as gains on 1p32-36, 6p21 and 17q21-22. Losses at 8p12-22 and 13q21-31 were observed more frequently in pT3 than pT2 tumors (Po0.05 and Po0.01, respectively). Losses at 8p12-22 were more frequent in tumors with BF (Po0.05), and those at 13q12-21 were more frequent in tumors with Gleason score (GS) 7 or more than lower GS (Po0.05). These findings suggest that losses of 8p12-22 and 13q21-31 are important determinants of prostate cancer progression.
Introduction
In many industrialized countries, prostate cancer is one of the most common male cancers. 1 In Japan, the morbidity and mortality of this disease is increasing year by year. Increased use of serum prostate-specific antigen (PSA) in screening has led to a remarkable increase in the number of newly detected prostate cancer cases. Most of these newly diagnosed tumors are at an early stage, and radical prostatectomy can be done in young patients with localized disease, and a long survival can be expected. However, some patients present with locally advanced disease or experience tumor progression after radical prostatectomy. At 10 years of follow-up, the progression-free survival rate of organ-confined prostate cancer (pT2) is 92%, whereas for locally advanced cancer (pT3%) it is 53%. 2 It is very difficult to predict which patients with rising PSA levels (biochemical failure (BF)) will progress rapidly to advanced disease. A better prognostic factor is needed to help clinicians determine the most appropriate therapies. There are many histological factors that can be used to predict prostatic cancer progression 3 however, molecular genetic factors which determine the prognosis of patients with this disease are poorly understood.
The identification of chromosomal aberrations with loss of heterozygosity (LOH), fluorescence in situ hybridization, and comparative genomic hybridization (CGH) analyses has identified several oncogenes and tumor suppressor genes (TSGs) that are involved in the progression of prostate cancer. [4] [5] [6] We have investigated several regions of chromosomal loss in prostate cancer using LOH analysis. [7] [8] [9] [10] [11] [12] [13] [14] [15] CGH is a molecular technique that allows screening of the whole genome for DNA sequence copy number alterations. Regions of increased copy number may contain oncogenes, whereas regions of decreased copy number may contain putative TSGs. In this study, we applied CGH to frozen tissue samples obtained from 30 cases of stage pT2N0M0 or pT3N0M0 prostate cancer. The aim was to determine additional chromosomal aberrations that may include oncogenes and TSGs responsible for localized prostate cancer.
Materials and methods

Patients
We examined 30 patients who had stage pT2 (10 cases) or pT3 (20 cases) primary prostate adenocarcinomas with no associated metastases (pN0M0), including 10 cases with BF after radical prostatectomy and 20 cases without BF. Histologically, the tumors were well differentiated in 30%, moderately differentiated in 40% and poorly differentiated in 30%. In this study, we defined BF as a serum PSA40.5 ng/ml after an undetectable postoperative PSA level. All patients had a radical prostatectomy at the Department of Urology, Chiba University Hospital, from April 1999 to September 2003; no patients were treated with endocrine therapy prior to surgery. All patients gave their informed consent for the research. The overall postoperative follow-up period was at least 2 years for all patients.
Laser capture microdissection (LCM)
Frozen tissue was obtained from radical prostatectomy specimens and embedded in optimal cutting temperature compound. Serial frozen sections (8 m) were cut on a CM1850 cryostat (Leica Microsystems, Wetzlar, Germany) with a clean blade at À20 1C and mounted on glass slides. The sections were stained with HistoGene Staining Solution using HistoGene LCM Frozen Section Staining Kit (Arcturus Engineering, Mountain View, CA, USA) according to the manufacturer's instructions. Benign and malignant histology was identified by a pathologist. Cancer cells were procured by the PixCell IIe LCM System (Arcturus). Approximately 2000 shots were fired for each cell population using CapSure HS LCM Caps.
Genomic DNA extraction and DNA amplification Genomic DNA extracted from laser-captured cells was prepared using the QIAamp DNA Micro Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The net DNA synthesis method was applied to amplify the extracted genomic DNA by using the random octamer primer reaction 16 and BioPrimeDNA Labeling System (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Comparative genomic hybridization (CGH)
CGH was carried out using the protocols of Vysis Inc. (http://www.vysis.com) and Fujisawa Pharmaceutical Co., Ltd (http://www.fujisawa.co.jp). Probes were made using a CGH Translation Kit (Vysis Inc., Downers Grove, IL, USA). Amplified tumor DNA was labeled with Spectrum Green-dUTP (Vysis), whereas reference DNA obtained from peripheral blood of normal Japanese men was labeled with Spectrum Red-dUTP (Vysis). Labeled tumor and normal DNA were co-precipitated with Human Cot-1 Blocking DNA (Vysis) by 100% ice-cooled ethanol. The precipitant was dissolved in CGH Hybridization Reagents (Vysis). The hybridization mixture was denatured at 75 1C for 6 min before use.
CGH Metaphase Target Slides (Vysis) were used as the slides containing normal metaphase spreads. After the slides were dried at 75 1C for 2 h on a slide warmer, the metaphase chromosomes were denatured separately in a formamide solution (70% formamide, 2 Â SSC) for 2 min and 10 s at 70 1C and dehydrated again through a series of graded solutions of 70, 90 and 100% ethanol.
The denatured probe mix was applied to the slides, which were then immediately covered by a cover glass and sealed with diluted rubber cement. The hybridization was carried out for 48 h at 37 1C in a humidified dark box. After hybridization, the slides were washed 3 times in wash solution (50% formamide, 2 Â SSC) for 10 min at 45 1C, 1 time each in 2 Â SSC for 6 min in 0.1 M PN-buffer (0.1 M NaH 2 PO 4 , 0.1 M Na 2 HPO 4 (pH 8.0)), then in 0.1% Nonidet P-40 for 7 min at room temperature, and finally in milli-Q for 5 min at room temperature. After airdrying the hybridized slide, DAPI II was applied onto the hybridization area for counter-staining.
CGH digital image and data analysis
CGH slides were captured and analyzed by the use of a CW4000-CGH (Leica Microsystems) equipped with a triple (DAPI/Green/Red) band-pass filter set (Vysis), and with a monochrome digital camera (Leica Microsystems). Gains and losses were determined by setting the ratio thresholds in the CGH imaging system to above 1.20 and below 0.80, respectively, (Kallioniemi et al.
18
). Chromosomes 16p, 19 and 22, and the Y chromosome, as well as acrocentric regions of chromosomes 13, 14, 15 and 21 and telomeres of all chromosomes, were excluded from the analysis, due to unpredictable hybridization and/or difficulty with the algorithms in the image analysis program. To search any specific genomic alteration in Japanese men, we also performed CGH analysis on normal Japanese male DNA hybridizing with normal white male DNA. Loss of 9q13-21 was detected 50% of the cases. Cavalli et al. 17 reported that the mean C-band size of chromosome 9 is significantly lager in Caucasian than in Japanese males. We excluded this region due to the possibility of Japanese genetic traits.
Statistical analysis
Variables such as age, PSA, BF, histological grade, Gleason score (GS) and postoperative observation period were tested for associations with clinical stage. For statistical purpose, prostate cancer samples were divided into two grade categories (low GS: GS%6, high GS: GS^7). Fisher's exact test and unpaired student t-test were applied. The most frequent aberrant chromosomal regions, which were found in 420% of the cases, were tested for associations with pathological stage, GS, BF and histological grade by Fisher's exact test. To evaluate the relative contribution of genetic and clinical variables to the prediction of BF, log-rank survivorship analysis and multivariate analysis (proportional hazards model) were applied. Pathological stage, GS, loss of 8p12-22 and loss of 13q21-31 were entered in this model. A value of Po0.05 was considered to indicate statistical significance.
Genetic changes in pT2 and pT3 prostate cancer S Fukasawa et al Table 2 ). All tumors had some chromosomal abnormalities detected by CGH. We compared chromosomal losses and gains for pathological stage, GS, BF and histological stage. The frequency of losses at chromosome arms 8p12-22 and 13q21-31 increased significantly in pT3 rather than pT2 tumors (P ¼ 0.011 and 0.005, respectively). In the subset of high GS, an increased frequency of genomic losses of 13q21-31 was detected compared to the low GS (P ¼ 0.025). Loss of 8p12-22 was mostly observed in BF ( þ ) rather than BF (À) (P ¼ 0.045) ( Table 3) . Losses of 2q23-24, 4q26-28, and 6q14-22 and gains of 1p32-36, 6p21 and 17q21-22 had no significant association with clinical stage, GS or BF. Histological grade had no relation with any chromosomal aberrations (Table 3) . To evaluate the relative contribution of these clinical variables (pathological stage and GS), loss of 8p12-22 and loss of 13q21-31 to the prediction of BF, log-rank survivorship analysis and multivariate analysis (proportional hazards model) were applied.
Results
Of all 30 patients, 10 (33.3%) were failed biochemically during the study period. Only the presence of loss of 8p12-22 had a correlation with recurrence-free survival in univariate and multivariate analysis (Table 4) .
Discussion
During postoperative follow-up of patients with prostate cancer, clinicians carefully monitor serum PSA levels. Unfortunately, there are no genetic markers that predict which patients will progress rapidly to advanced disease following BF (rising PSA levels). In this study, we did a genome-wide survey of DNA sequence copy number changes using CGH in 30 primary prostate cancers (stages pT2 and pT3). The CGH method allows a comprehensive analysis of chromosomal imbalances in a single assay with no need to have previous knowledge of the candidate regions to be investigated. 18 To identify putative TSGs or oncogenes, it is important to find the same chromosomal regions of losses or gains in different tumor samples. The regions of minimal overlap may contain the respective target genes.
Studies of DNA copy alterations in prostate cancers have detected multiple frequently altered regions in the genome so far. Sun et al. 19 performed a combined analysis of all published CGH studies of prostate cancer (41 studies examining 892 cancers) and estimated the frequency of alterations across the genome for all tumors. They reported that chromosome 8p was the most commonly deleted region. Loss of 8p21.3 was detected 34.1% of the cases and 56.3% of the advanced tumors. The second most commonly deleted region was observed at 13q21-31 (28.0%). Other commonly deleted regions, which were observed in more than 10% of the cases, were 6q14.1-6q21 (22.24%), 16q13-16q24.3 (17.85%), 18q12.1-18q23 (12.80%), 5q13.3-5q21.3 (13.06%), 2q21.2-2q22.3 (12.42%) and 10q23.1-10q25.3 (11.76%).
Chromosome 8q was the most commonly gained region in their study. Gain of 8q22.2 was detected in In the present study, we used frozen tissue obtained during radical prostatectomy instead of archival samples (such as formalin-fixed and paraffin-embedded samples), which would contain truncated cells, for more accurate and reliable CGH analyses. Previous reports Genetic changes in pT2 and pT3 prostate cancer S Fukasawa et al have shown that DNA prepared from fresh tissue has a higher rate of successful hybridization than that prepared from archival materials. 20 Using these fresh samples, we could obtain cancer cells of high purity using LCM. The use of strict criteria and modified techniques, as described above, allowed us to detect several chromosomal abnormalities in pT2 and pT3 prostate cancers.
Chromosomal losses
In the present study, the region most frequently involved in chromosomal loss was 13q21-31. Loss of 13q21-31 was observed more frequently in pT3 tumors and tumors with high GS. Losses of 13q have been consistently observed in prostate cancer. 5, 6 LOH analyses have also demonstrated several distinct commonly deleted regions on 13q. 4 Mckie et al. 21 have recently reported epigenetic inactivation of the human sprouty2 (hSPRY2) homologue, maps to 13q31.1, in prostate cancer. Sprouty2 is Genetic changes in pT2 and pT3 prostate cancer S Fukasawa et al a key antagonistic regulator of receptor tyrosine kinases signaling and suppression of its expression or function may facilitate proliferation and angiogenesis. Loss of 8p12-22 was frequently observed in pT3 tumors and cases with BF. Chromosomal arm 8p has been one of the most intensively studied regions of loss in prostate cancer. In this study, there was a minimal overlapping region at 8p12-22. Chromosomal region 8p22 contains the known putative TSGs MSR1 and N33. 22, 23 He et al. 24 mapped the NKX3.1 gene to 8p21, which is a human prostate-specific, androgen-regulated homeobox gene. Many studies indicate that loss of 8p12-21 is an early event in prostate carcinogenesis, whereas loss of 8p22 is a later event that is common in advanced prostate cancers. In this study, loss at 8p12-22 was more frequent in pT3 tumors than in pT2 tumors. Survival analysis showed that loss of 8p12-22 was the best indicator of BF even when GS and clinical stage were taken into account.
In this study, losses of 2q, 4q and 6q were also frequently observed, whereas none of these losses were associated with pT classification, GS or BF. Recent LOH studies on prostate cancer have demonstrated several distinct commonly deleted regions on chromosome 2.
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One of such regions, 2q23.1-32.1, is overlapped with the region observed in the present study. Losses of 4q have been also observed frequently in prostate cancer. 5 Recent high-resolution analysis has demonstrated that a consistent 4.5 Mbp deletion at 4q28. 25 These regions on 2q and 4q, which are consistent with our study, may contain candidate TSGs and may play important roles in the progression of prostate cancer. Recent detailed studies have shown that loss of 6q occurs frequently in human prostate cancers. CGH and cytogenetic studies have shown that frequent genetic alterations occur in the 6q15-22 region and indicate that 1 or more TSGs are located there. [26] [27] [28] [29] [30] Three potential candidate genes are present in this region, and they encode cell-cycle regulatory protein cyclin C, thiol-specific antioxidant protein 1 and the glutamate receptor iontropic kainate 2.
Loss of 10q has been identified in a significant percentage of prostate carcinomas. However, we could not detect frequent loss of this region. Loss of 10q is considered to be associated with advanced clinical stage and aggressive behavior in prostate cancer. Our previous LOH study, 9 10q loss was observed in 50% of advanced cases. However, such loss was observed less frequently in localized tumors (0% of stage B, 17% of stage B þ C), which is consistent with the present study.
Chromosomal gains
In this study, frequent gains were observed at 1p32-36, 6p21 and 17q21-22. However, none of those gains were associated with pT classification, GS or BF. Phillips et al.
31
found 1p13-33 gain in preserved prostate epithelial cells (BPH CAFTD -01 and -03). Thus, amplification of 1p might not be a chromosomal aberration peculiar to prostate cancer. Chromosomal arm 6p, specifically band 6p21, is known to locate cyclin D3, whose high expression has been identified in gastric cancer. 32 Chromosome arm 17q contains the candidate oncogene c-erbB-2 (HER-2/neu) at 17q21-22. It is highly homologous to the epidermal growth factor receptor, and encodes a 185 kDa transmembrane protein (p185) with tyrosine kinase activity. 33 
Table 3
Relationship between commonly observed chromosomal aberrations and clinicopathological parameters Fisher's exact probability test was used.
Genetic changes in pT2 and pT3 prostate cancer S Fukasawa et al
It has been shown that c-erbB-2 gene amplification and/or overexpression in primary breast cancer is an independent biomarker of poor prognosis and has been shown to enhance the malignant potential and metastatic phenotypes. 34, 35 Bubendorf et al. 36 however did not detect c-erbB-2 amplification at any stage of prostate cancer progression.
8q24 is known as the most commonly gained region in prostate cancer where C-MYC exists. Recently several studies have suggested that 8q24 amplification is a stronger risk factor for aggressive prostate cancer. It has been detected more frequent in advanced-stage tumors than in early-stage tumors, in high-grade tumors than in low-grade tumors and in poorly differentiated tumor morphology than well or moderate tumor morphology. 37 In our study, 8q24 amplification more than 20% was not detected. Our tumor samples were all operable, not including metastatic samples, and they were considered not as aggressive, in regard to pathological stage, BF, GS and histological grade, as to show the prominent 8q24 amplification.
In this study, losses at 8p12-22 and 13q21-31 were observed more frequently in pT3 tumors. Moreover, losses at 8p12-22 were more frequent in tumors with BF, and those at 13q21-31 were more frequent in tumors with high GS. However, the other frequent observed aberrations (losses at 2q23-24, 4q26-28 and 6q14-22; gains at 1p32-36, 6p21 and 17q21-22) were not associated with pathological grade, neither GS nor BF. Recently, Ribeiro et al. 6 have demonstrated a genetic pathway of prostate carcinogenesis with two distinct initiating events, 8p and 13q losses. These two distinct losses are then followed by 8q þ , 6qÀ, 16qÀ and 18qÀ, resulting in progression from organ confined to locally invasive prostate cancers. These findings have been obtained by a meta-analysis on a total of 294 prostate cancers with detailed CGH and clinicopathological information.
Our study has also suggested a significant role of losses of 8p and 13q during progression of prostate cancer, although there seem to be no such genetic pathways reported by Ribeiro et al. 6 In our survival analysis, loss of 8p had significant relation with BF, whereas no relationship was observed between 13q and BF. This finding might be due to the smaller number of samples examined in our study and to the characteristic of Japanese prostate cancers. Matsuda et al. 38 suggested that Japanese prostate cancers had rare event of 13q loss in primary tumors and when it occurs, it is a late event.
A larger number of cases may allow us to identify more chromosomal aberrations that relate with tumor progression.
The chromosomal regions detected by our CGH analysis are still too long to identify individual gene. To overcome the limitation of chromosomal CGH, arraybased CGH has been developed. 39, 40 We are currently using array-based CGH to examine the regions that were identified in the present study. 
